IMMX

Immix Biopharma, Inc. [IMMX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IMMX Stock Summary

Top IMMX Correlated Resources

IMMX

Top 10 Correlated ETFs

IMMX

Top 10 Correlated Stocks

IMMX

In the News

IMMX Financial details

Company Rating
-
Market Cap
72.85M
Income
-15.44M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
14
Optionable
No
Shortable
Yes
Earnings
29 May 2024
P/E
-8.36
Forward P/E
-
PEG
-1.79
P/S
-1.4
P/B
5.98
P/C
-
P/FCF
-9.91
Quick Ratio
7.16
Current Ratio
7.9
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.91
EPS next Y
-
EPS next Q
-
EPS this Y
43.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
13.04%
-
-
-
-
SMA20
50%
SMA50
50%
SMA100
50%
Inst Own
-
Inst Trans
-
ROA
-63%
ROE
-98%
ROC
-0.74%
Gross Margin
100%
Oper. Margin
16%
Profit Margin
16%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.4-7.75
52W High
-60.71%
52W Low
+175%
RSI
56
Rel Volume
1.01
Avg Volume
283.91K
Volume
286.94K
Perf Week
-3.51%
Perf Month
20.61%
Perf Quarter
36.14%
Perf Half Y
43.23%
-
-
-
-
Beta
0.049
-
-
Volatility
0.06%, 0.28%
Prev Close
0%
Price
2.75
Change
1.85%

Something similar

Top by Market Cap
BRK-B
LLY
BRH.DE
AVGO
BRYN.DE
Top Correlated ETFs
SATO
BLKC
BDRY
RCD
PFFA
Top Correlated Stocks
MGTX
INBX
ELDN
GREE
PRA
Similar Market Cap
ISXF.L
FHLT
0430.HK
OPI
HZU.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 283.91K
  • Market Capitalization 72.85M
  • Employee 14
  • CEO Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
  • Headquarters Los Angeles,CA,US
  • IPO Date 2021-12-16
  • Website https://www.immixbio.com

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.